Toxic epidermal necrolysis: Performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China

Journal of Burn Care and Research

Volumn 33, Issue 6, 2012, Pages

  Zhu, Qin Yuan ^a   Ma, Li ^a   Luo, Xiao Qun ^a   Huang, Hui Yuan ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; METHYLPREDNISOLONE;

ADULT; AGED; ARTICLE; CHINA; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; SCORING SYSTEM; SEVERITY OF ILLNESS SCORE FOR TOXIC EPIDERMAL NECROLYSIS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; AREA UNDER CURVE; BIOPSY; CHI-SQUARE DISTRIBUTION; CHINA; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; INTENSIVE CARE UNITS; MALE; METHYLPREDNISOLONE; RETROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84870334392     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e318254d2ec     Document Type: Article

References (40)

1. Wolkenstein P, Roujeau JC. Epidemiology of toxic epidermal necrolysis. European J Dermatol 1994;4:175-80. (Pubitemid 24152428)
2. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996;49:769-73. (Pubitemid 26280728)
3. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-6. (Pubitemid 23029676)
4. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005;209:123-9.
5. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53. (Pubitemid 30637181)
6. Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, et al. Performances of the SCORTEN during the first five days of hospitalisation. J Invest Dermatol 2004;123:272-6.
7. Collin B, Marshall T, Heagerty A. Scoring with SCORTEN. Arch Dermatol 2003;139:1215.
8. Trent JT, Kirsner RS, Romanelli P, et al. Scoring with SCORTEN-Reply. Arch Dermatol 2003;139:1215-16.
9. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol 2004;140:890-2. (Pubitemid 38917869)
10. Cartotto R, Mayich M, Nickerson D, Gomez M. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center. J Burn Care Res 2008;29:141-6.
11. Sekula P, Liss Y, Davidovici B, et al. Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res 2011;32:237-45.
12. Lissia M, Figus A, Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg 2005;58:504-10. (Pubitemid 40645392)
13. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol 2003;139:39-43. (Pubitemid 36091572)
14. Imahara SD, Holmes JH 4th, Heimbach DM, et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J Burn Care Res 2006;27:270-5. (Pubitemid 43970289)
15. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003;139:33-6. (Pubitemid 36091571)
16. Quinn AM, Brown K, Bonish BK, et al. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol 2005;141:683-7. (Pubitemid 41001067)
17. Oplatek A, Brown K, Sen S, Halerz M, Supple K, Gamelli RL. Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res 2006;27:26-33. (Pubitemid 43970339)
18. Xu JH, Yang YS, Li F, et al. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China. Int J Dermatol 2009;48:1122-8.
19. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986;204:503-12. (Pubitemid 17176768)
20. Schlingman J, Mockenhaupt M, Fagot JP, et al. Evaluation of treatment efficacy in a cohort of 281 patients with Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). J Invest Dermatol 2004;123:367.
21. Criton S, Devi K, Sridevi PK, Asokan PU. Toxic epidermal necrolysis-a retrospective study. Int J Dermatol 1997;36:923-5. (Pubitemid 28053894)
22. Wolff K, Tappeiner G. Treatment of toxic epidermal necrolysis: the uncertainty persists but the fog is dispersing. Arch Dermatol 2003;139:85-6. (Pubitemid 36091582)
23. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-3. (Pubitemid 28483679)
24. Magina S, Lisboa C, Gonçalves E, Conceiçäo F, Leal V, Mesquita-Guimaräes J. A case of toxic epidermal necrolysis treated with intravenous immunoglobin. Br J Dermatol 2000;142:191-2. (Pubitemid 30074505)
25. Prins C, Kerdel FA, Padilla RS, et al.; TEN-IVIG Study Group. Toxic epidermal necrolysis-intravenous immunoglobulin. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139:26-32. (Pubitemid 36091570)
26. Stella M, Cassano P, Bollero D, Clemente A, Giorio G. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology (Basel) 2001;203:45-9. (Pubitemid 32830530)
27. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004;25:81-8. (Pubitemid 38116760)
28. Sekula P, Schneck J, Fagot JP, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol 2008;58:33-40. (Pubitemid 350298143)
29. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301-8.
30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
31. Liddell FD. Simple exact analysis of the standardised mortality ratio. J Epidemiol Community Health 1984;38:85-8. (Pubitemid 14155849)
32. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36. (Pubitemid 12142173)
33. Lemeshow S, Hosmer DW Jr. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982;115:92-106. (Pubitemid 12205725)
34. Kim KJ, Lee DP, Suh HS, et al. Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients. Acta Derm Venereol 2005;85:497-502. (Pubitemid 43087286)
35. Wu SC, Ho YL, Chang YT, et al. Performance of the SCORTEN in Taiwanese patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Dermatologica Sinica 2010;28:15-20.
36. George SM, Harrison DA, Welch CA, Nolan KM, Friedmann PS. Dermatological conditions in intensive care: a secondary analysis of the Intensive Care National Audit and Research Centre (ICNARC) Case Mix Programme database. Crit Care 2008;12 (Suppl 1):S1.
37. Spornraft-Ragaller P, Theilen H, Gottschlich G, et al. Treatment of toxic epidermal necrolyis. Experience with 9 patients with consideration of intravenous immunoglobulin. Hautarzt 2006;57:185-194.
38. Vaishampayan SS, Das AL, Verma R. SCORTEN: does it need modification? Indian J Dermatol Venereol Leprol 2008;74:35-7.
39. Hague JS, Goulding JM, Long TM, Gee BC. Respiratory involvement in toxic epidermal necrolysis portends a poor prognosis that may not be reflected in SCORTEN. Br J Dermatol 2007;157:1294-6. (Pubitemid 350115695)
40. Chen J, Wang B, Zeng Y, Xu H. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases. Eur J Dermatol 2010;20:743-7.